TD Cowen analyst Tyler Van Buren has maintained their neutral stance on ARVN stock, giving a Hold rating on October 28.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren has given his Hold rating due to a combination of factors related to Arvinas Holding Company’s current pipeline and clinical trial results. The company’s early-stage pipeline is expanding rapidly, with several promising candidates like ARV-102 and ARV-393 showing potential in their respective trials. However, the mixed data underpinning the NDA filing for vepdeg, despite its statistical significance, raises concerns about its ability to significantly differentiate in its class.
Furthermore, while ARV-102 has shown robust target engagement in early trials, the diminishing incremental effect at higher doses suggests potential limitations. The collaboration with Pfizer for vepdeg commercialization and the anticipated partnership ahead of the PDUFA date are positive developments, yet the overall uncertainty in clinical outcomes and competitive landscape contributes to the Hold rating. These factors collectively suggest a cautious approach, balancing potential growth with existing risks.
In another report released on October 28, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $10.00 price target.